Tenet Healthcare Reports Strong Q2 Results, Raises Full-Year Outlook, and Boosts Buyback by $2.0 Billion
THC sits 36% above its 52-week low of $146.6.
Summary
Tenet Healthcare reported robust Q2 earnings, raised its full-year financial outlook, and authorized a substantial $2.0 billion increase to its share repurchase program.
Key Events · Earnings and Guidance · THC
-
Strong Q2 Financial Performance
Net income available to common shareholders surged to $826 million ($9.84 diluted EPS) in Q2 2026, up from $288 million ($3.14 diluted EPS) in Q2 2025. Adjusted diluted EPS increased 52.2% to $6.12, and Consolidated Adjusted EBITDA grew 16.3% to $1.304 billion.
-
Raised Full-Year Guidance
The company increased its FY 2026 Adjusted EBITDA outlook by $295 million at the midpoint to a new range of $4.83 billion to $5.03 billion. The FY 2026 Adjusted Free Cash Flow outlook was also raised by $225 million at the midpoint.
-
$2.0 Billion Share Buyback Increase
The Board of Directors authorized a $2.0 billion increase to the existing share repurchase program, bringing the total remaining authorization to $2.13 billion. This follows $1.042 billion in repurchases during Q2 2026.
Analysis · THC · Industrial Applications And Services
The company delivered strong second-quarter financial results, significantly exceeding prior-year performance and analyst expectations. This strong operational execution led to a substantial increase in full-year financial guidance. Furthermore, the board authorized a significant $2.0 billion increase to its share repurchase program, demonstrating strong confidence in future performance and a commitment to returning capital to shareholders.
At the time of this filing, THC was trading at $199.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $17.1B. The 52-week trading range was $146.60 to $247.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.